- Coordinator
- Institut Pasteur, France
- Runs
- 1 October 2022 to 30 September 2027
- Status
- Running
- EU funding
- €7.3m
- Total cost
- €7.3m
- Partners
- 9 organisations in 9 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101057665
What the project is doing
In the project's own words, from its summary on CORDIS.
P. vivax is considered the most difficult human malaria to eliminate because of the inability of conventional diagnostics to detect individuals with latent liver forms. These individuals account for 80% of all infections and can readily infect mosquitoes. Currently countries can test knowing this has little impact or and the treat everyone which exposes individuals to drugs with potentially dangerous side effects. Parasite specific antibody responses have been shown to correlate with the likelihood of hypnozoite carriage and can be used to identify individuals who should be treated.
Aim is to implement a Cluster-Randomised Trial in Ethiopia and Madagascar to demonstrate the effectiveness of a new anti-malaria intervention based on Plasmodium vivax serological testing and treatment (PvSTATEM) with primaquine to prevent the relapse infections responsible for maintaining P. vivax transmission. Simultaneously, we will assess social and health system acceptability of such an approach as well as refine new mobile technologies which interface with point-of-care diagnostic tests and guide treatment decisions.
We aim to reduce malaria burden at both the individual and population level in two countries which experience the highest levels of P.vivax in Africa. We expect to have a significant effect in reducing morbidity and improving health. We will ensure community engagement and assess the adoption of new technologies that align with those existing in the health system. The proposal is built on equal partnership and shared capacity to address a substantial public health burden.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Institut Pasteur | Paris | France | Coordinator |
| The Walter and Eliza Hall Institute of Medical Research Public Companylimited by Guarantee | Parkville | Australia | Associatedpartner |
| Foundation for Innovative New Diagnostics | Geneve | Switzerland | Participant |
| Armauer Hansen Research Institute | Addis Ababa | ET | Participant |
| University of Galway | Galway | Ireland | Participant |
| Medea SRL | Massa Ms | Italy | Participant |
| Institut Pasteur de Madagascar | Antananarivo | MG | Participant |
| Politechnika Warszawska | Warszawa | Poland | Participant |
| London School of Hygiene and Tropical Medicine Royal Charter | London | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI